Compare NRIM & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRIM | STTK |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 604.2M | 538.3M |
| IPO Year | 2002 | 2020 |
| Metric | NRIM | STTK |
|---|---|---|
| Price | $27.14 | $7.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 175.7K | ★ 1.9M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $255,581,000.00 | $1,000,000.00 |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | $44.51 | ★ N/A |
| Revenue Growth | ★ 30.43 | N/A |
| 52 Week Low | $19.60 | $0.71 |
| 52 Week High | $95.61 | $8.33 |
| Indicator | NRIM | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 53.35 | 58.96 |
| Support Level | $25.99 | $5.87 |
| Resistance Level | $28.31 | $7.64 |
| Average True Range (ATR) | 0.97 | 0.62 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 51.56 | 71.63 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.